Back to search results

Indoor Air Filtration for Heart Disease

This study is looking at whether using HEPA (High Efficiency Particulate Air) filters in your home can help slow down the progression of atherothrombosis (a condition where plaque builds up in your arteries) in adults who have a history of ischemic heart disease (heart problems caused by narrowed arteries). Participants will use either a HEPA filter or a sham filter (looks the same but without the filter) in their homes over a 21-month period. Researchers will measure changes in your blood pressure and other vascular function markers to see if the HEPA filters make a difference. We are looking for 112 participants, aged 65 to 84, who have a history of ischemic heart disease, are non-smokers, and live in Los Angeles. The current status of this study is unclear.

Study design
This is a double-blind, randomized, crossover study involving 112 adults. This means neither you nor the researchers will know if you are using the HEPA filter or the sham filter at any given time, and you will experience both interventions.
What's involved
You would participate in a 21-month study period, which includes two 9-month intervention periods (one with HEPA filtration and one with sham filtration) and a 3-month break in between. Project specialists will visit your home to set up equipment, collect information, and measure your vascular function. You will also monitor your blood pressure daily.
Compensation
Not stated in the trial record.
Follow-up
Blood pressure will be monitored daily during each 9-month intervention period. Other measurements will be taken at the beginning, middle (4.5 months), and immediately after each 9-month intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05867381

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

Recruiting
NAAges 65–84InterventionalPrevention
University of Southern California
~112 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:HEPA filtrationSham filtration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in blood pressure
Measured over Blood pressure will be monitored daily during each of the 9-month intervention
+4 more outcomes measured

Conditions

Air Pollution
Atherosclerosis

Explore related trials

AtherosclerosisIschemic Heart Disease

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Zhanghua Chen, PhD · PRINCIPAL_INVESTIGATOR · University of Southern California
  • Junfeng Zhang, PhD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Zhanghua Chen, PhD
[email protected]
323-442-2109
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age between 65 and 84 years old;
Weight ≥ 110 pounds;
Nonsmokers for at least 1 year;
Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;
Both English and Spanish speaking participants will be included in the recruitment;
Live in the Los Angeles County.

Exclusion

Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;
Currently have active cancer treatments;
The residential house has already had HEPA filters;
Participants will move out from the current residential address in the next 2 years;
Participants will spend more than 1 month living outside the primary home;
Have any health conditions that prohibit collecting health and covariate data and biospecimens;
Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.

What this trial measures

  • Change in blood pressureBlood pressure will be monitored daily during each of the 9-month intervention

    Differences between baseline and systolic and diastolic blood pressure measured during and after intervention

  • Change in carotid-femoral pulse wave velocityAt the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions

    Differences between baseline and carotid-femoral pulse wave velocity measured with Vicorder device during and after intervention

  • Change in augmentation indexAt the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions

    Differences between baseline and augmentation index measured with Vicorder device during and after intervention

  • Change in von Willebrand factorAt the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions

    Differences between baseline and von Willebrand factor measured during and after intervention

  • Change in P-selectinAt the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions

    Differences between baseline and P-selectin measured during and after intervention